Role of NIK Activation in Melanoma Progression
Role of NIK Activation in Melanoma Progression
批准号:
7229584
负责人:
Ann Richmond
金额:
$25.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-07 至 2010-04-30
关键词:
ApoptosisCellsDevelopmentEventGenesGenetic TranscriptionGrowthLaboratoriesLeadMalignant NeoplasmsMediatingMutationNF-kappa BNuclearNumbersPhosphotransferasesProtocols documentationReagentRegulator GenesRoleSignal TransductionStagingTherapeuticTherapeutic InterventionTumor Suppressor ProteinsWorkbasedesigninsightmelanomaneoplastic cellnovel therapeuticstumor growthtumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A key event in the development of melanoma is the mutation of key cell regulatory genes resulting in loss of tumor suppressors and endogenous expression of angiogenic and growth regulatory factors. The constitutive activation of nuclear factor-kappa beta (NF-kappaB) during tumorigenesis has been extensively documented in our lab, and a number of other laboratories. We have demonstrated that during melanoma tumor progression, IKKalpha-beta become constitutively activated, leading to nuclear activation of NF-kappaB, which in turn facilitates escape from apoptosis and immortalization of tumor cells. We have observed that coordinate with the activation of NF-kappaB is enhanced activation of the NF-kappaB inducing kinase, NIK. We hypothesize that NIK is activated by an upstream effector during tumor progression and these events lead to enhanced NF-kappaB mediated transcription and tumor progression. We propose to characterize the mechanism for the activation of NIK and NF-kappaB, and to develop protocols which explore new therapeutic intervention for melanoma based upon our findings. The specific aims of this proposal are 1) To determine the mechanism by which NIK is constitutively activated during melanoma tumor progression; 2) To develop approaches to ablate constitutive NIK and NF-kkappa activity and block tumor growth; 3) To determine the stage in melanoma tumor progression where constitutive activation of NIK occurs. The work described in this proposal should provide insight for the development of therapeutic reagents designed to intervene in the progression and growth of tumors showing constitutive NIK activation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
-
批准号:10618231
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Ann Richmond
-
依托单位:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
-
批准号:10454101
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:10305634
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:9916443
-
项目类别:
-
资助金额:$37.65万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:10531596
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10609814
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10369756
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8817140
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10265337
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8633274
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8966669
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:8195848
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:7797846
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:7912888
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:8391117
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse
-
批准号:7915941
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting the NF-kappaB Pathway in Melanoma
-
批准号:7115276
-
项目类别:
-
资助金额:$29.51万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Targeting the NF-kappaB Pathway in Melanoma
-
批准号:7459854
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
-
批准号:8091397
-
项目类别:
-
资助金额:$32.84万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
-
批准号:7992308
-
项目类别:
-
资助金额:$14.95万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: